ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment

ET-02 showed significant hair growth in five weeks, outperforming minoxidil in a clinical trial with 24 participants.
The 5% ET-02 solution increased hair count six-fold and improved non-vellus hair width by 10%.
ET-02's non-hormonal mechanism avoids adverse effects of androgen inhibition treatments like finasteride.
The therapy targets inactive hair follicle stem cells, potentially treating hair loss and greying.
A phase 2 clinical trial with 150 patients is planned to further assess ET-02's efficacy and safety.